Data on gefitinib, another drug used in the treatment of NSCLC, which is a tyrosine kinase inhibitor targeting epidermal growth factor receptors or EGFRs, showed that gefitinib treatment coupled with miR-7 significantly decreased the IC50 of gefitinib, inhibited cell growth, increased G0/G1 cell cycle arrest, and increased apoptosis [68]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.